Low-Dose Sirolimus Immunoregulation Therapy in Patients with Active Rheumatoid Arthritis: A 24-Week Follow-Up of the Randomized, Open-Label, Parallel-Controlled Trial

BACKGROUND: We have reported previously the insufficient absolute number or functional defects of regulatory T cells (Tregs) in patients with rheumatoid arthritis (RA), challenging conventional unspecific immunosuppressive therapy. Sirolimus, a mTOR inhibitor, is reported to allow growth of function...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Hong-Yan, Wang, Jia, Zhang, Sheng-Xiao, Luo, Jing, Zhao, Xiang-Cong, Zhang, Chen, Wang, Cai-Hong, Hu, Fang-Yuan, Zheng, Xiao-Juan, Cheng, Ting, Niu, Hong-Qing, Liu, Guang-Ying, Yang, Wen-Xian, Yu, Na-Na, Ru, Jin-Li, Chen, Qi-Xiang, Lu, Xue-Chun, He, Pei-Feng, Gao, Chong, Li, Xiao-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874993/
https://www.ncbi.nlm.nih.gov/pubmed/31781682
http://dx.doi.org/10.1155/2019/7684352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874993/
https://www.ncbi.nlm.nih.gov/pubmed/31781682
http://dx.doi.org/10.1155/2019/7684352

Ejemplares similares